Tweet
Thalassemia is a hereditary hemoglobinopathy characterized by an inherited defect in the production of hemoglobin, the protein in red blood cells responsible for carrying oxygen throughout the body. This genetic disorder leads to anemia, a condition where the body doesn't have enough healthy red blood cells to function effectively. As a result, individuals with thalassemia may experience fatigue, weakness, pale skin, and other symptoms.
Affecting a significant portion of the global population, nearly 5.2% of individuals worldwide carry abnormal hemoglobin genes associated with thalassemia. This disease represents a prevalent and ongoing health concern, especially when considering that each year, hundreds of thousands of children are born with severe hemoglobinopathies. Tragically, a majority of these cases occur in developing countries, where access to appropriate medical care may be limited.
Southern China, particularly Ganzhou in the Jiangxi province, has recorded high rates of thalassemia. A recent study published on August 18, 2023, in Human Genomics sought to understand the prevalence and mutation spectrum of thalassemia in this region. Led by researchers Tong Yang, Xuemei Luo, Yanqiu Liu, and Wenqian Zhang of BGI Genomics, the team built upon previous, smaller-scale studies to analyze data from an expansive screening project that included 136,312 individuals.
Exploring the Data
The research specifically looked at participants from the "Implementation Plan for the Free Gene Detection of Thalassemia in Ganzhou City (2019–2022)". Their findings include:
- The detection of 19,827 thalassemia carriers within the sampled population. This included individuals with α-thalassemia, β-thalassemia, and both α- and β-thalassemia.
- The identification of 156 distinct thalassemia genotypes. Notably, 48 rare mutations were detected.
- A noticeable concentration of thalassemia cases in southeastern Jiangxi Province, particularly in Dingnan and Xunwu, which had prevalence rates of 18.3% and 17.7%, respectively.
Advantages of Next-Generation Sequencing
One of the major takeaways from this research is the efficacy of next-generation sequencing (NGS) in identifying thalassemia mutations. The team observed that NGS techniques were superior to traditional genetic screening methods. Conventional methods, which often rely on hematological analysis and polymerase chain reaction (PCR), frequently miss or misdiagnose many novel or rare thalassemia variations due to their inherent limitations. Moreover, NGS has proven to be a cost-effective choice for prenatal screenings.
The study's findings underline the critical nature of thalassemia as a public health issue in the Ganzhou region. Moreover, by identifying rare variations in thalassemia genes, the study underscores the importance of utilizing NGS for comprehensive and accurate thalassemia screening in large populations.
Read the original publication in Human Genomics here.
